Drugs / Lefradafiban
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02265289 | Jan → Feb 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264106 | Apr → Jun 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264119 | Apr → Jul 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lefradafiban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02264119 ↗ |
| Modality | Small molecule | — CHEMBL2105032 ↗ |
| Route | Oral | “Multiple Oral Doses of 30 mg Lefradafiban” NCT02264106 ↗ |